Join the club for FREE to access the whole archive and other member benefits.

Insilico raises $255M to advance human trials and AI drug discovery platform

22-Jun-2021

Key points from article :

Insilico Medicine closes $255 million to progress into human trials, initiate new programmes for novel and difficult targets, and develop its AI and drug discovery capabilities.

Collaborated with Teva Pharmaceutical Industries Ltd to identify novel therapeutic targets in various diseases.

The first case of AI identifying a novel target for a pulmonary disease, generating novel molecules, and completing the preclinical experiments in under 18 months.

Developed PandaOmics AI-powered novel target discovery engine, Chemistry42, InClinico.

“The AI technologies are...delivering valuable and absolutely novel therapeutic assets with high probability of clinical success,” - Alex Zhavoronkov, CEO of Insilico Medicine.

Technologies available for licensing for the pharmaceutical and biotechnology companies.

7 out of the top 30 pharmaceutical companies deployed its software.

Started a drug discovery team and platform in China.

More information on Insilico and its research will be available at ARDD.

New collab with Teva Pharmaceuticals to identify drug targets for various diseases

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Academic

CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation.

Event

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.

Company

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Company

Company developing, producing and marketing affordable, high quality generic drugs and specialty pharmaceuticals.